This conference book is your guide to our annual Local Champions Mid Cap Conference set to take place on Thursday, 11 December 2025 at our historic building at Grand Place in Brussels. This event offers the possibility to have one-on-one meetings and/or attend small group sessions with the top management and/or IR of the following companies: BARCO | BEKAERT | DECEUNINCK | DEME | EVS | IBA | JENSEN GROUP | MATERIALISE | ONTEX | PROXIMUS | RECTICEL | XFAB
NEXTENSA ACHIEVES SOLID RESULTS IN Q3 REGULATED INFORMATIONBrussels, 13 November 2025, 5:55 PM RESULTS ON Q3 2025 HIGHLIGHTS NEXTENSA ACHIEVES SOLID RESULTS IN Q3 In the third quarter of 2025 Nextensa maintained its strong momentum and achieved a clear increase in profitability. Net profit increased significantly, driven by a higher contribution of development activities, lower financing costs and a further strengthening of the balance sheet. Three significant transactions were completed in Q3 2025: Sale of Retail Estates. On August 28,2025, Nextensa has sold its entire 8.99% sta...
NEXTENSA RÉALISE DES RÉSULTATS SOLIDES EN Q3 INFORMATION RÉGLEMENTÉEBruxelles, 13 novembre 2025, 17h55 RESULTATS POUR LE Q3 2025 FAITS MARQUANTS NEXTENSA RÉALISE DES RÉSULTATS SOLIDES EN Q3 Au troisième trimestre 2025, Nextensa a poursuivi son élan positif en enregistrant une croissance nette de sa rentabilité. Le bénéfice net a connu une progression significative, soutenu par la contribution accrue des activités de développement, la diminution des coûts de financement et le renforcement continu de son bilan. Trois opérations significative majeures ont été finalisées au Q3 2025. :...
NEXTENSA ZET SOLIDE RESULTATEN NEER IN Q3 GEREGLEMENTEERDE INFORMATIEBrussel, 13 november 2025, 17h55 RESULTATEN OVER Q3 2025 HIGHLIGHTS NEXTENSA ZET SOLIDE RESULTATEN NEER IN Q3 In het derde kwartaal van 2025 behield Nextensa zijn sterke momentum en realiseerde het een duidelijke stijging van de rentabiliteit. De nettowinst steeg aanzienlijk dankzij een hogere bijdrage van de ontwikkelingsactiviteiten, lagere financieringskosten en een verdere versterking van de balans. In Q3 van 2025 werden drie significante transacties afgerond: Verkoop van Retail Estates. Op 28 augustus 2025 he...
The 3Q25 results were a slight miss versus expectations due to a more negative impact from mix in Parcels. PostNL has taken some efficiency measures to compensate and hence reiterated its outlook for FY25. However, we feel the outlook is challenging given that 4Q25F will need a significant uplift vs 4Q24. Election mail and yield/efficiency measures provide support but mix and uncertain customer confidence and close clustered timing of festive events lead us to remain a bit more cautious for 4Q25...
We updated our model (new € 67.5 Target Price (from €62) after Jensen-Group's 3Q25 revenues came in at a very nice € 134.9m compared to € 107.5m in 3Q24, resulting in a 19% y/y higher 9M25 sales of € 398.0m. We maintain our Accumulate rating. We incorporated in our updated model that Jensen-Group highlighted that after very solid results in the first nine months, they remain on track to deliver a record year with an expected FY25 EBIT range € 66m and € 71m (KBCSe from 64.9m to € 69m). On the ...
PUBLICATION OF ATRANSPARENCY NOTIFICATION - ACKERMANS & VAN HAAREN PUBLICATION OF ATRANSPARENCY NOTIFICATION - ACKERMANS & VAN HAAREN Pursuant to article 14 of the law of 2 May 2007, Nextensa NV/SA announces that it has received a transparency notification dated 30 October 2025 from Ackermans & van Haaren NV/SA (having its registered offices at Begijnenvest 113, 2000 Antwerp, Belgium). Ackermans & van Haaren has notified that, following an acquisition of additional shares on 28 October 2025, its total number of voting rights in Nextensa increased to 80.31% of the voting rights. Based o...
PUBLICATION D’UNE NOTIFICATION DE TRANSPARENCE – ACKERMANS & VAN HAAREN PUBLICATION D’UNE NOTIFICATION DE TRANSPARENCE – ACKERMANS & VAN HAAREN Conformément à l'article 14 de la loi du 2 mai 2007, Nextensa SA annonce avoir reçu une déclaration de transparence datée du 30 octobre 2025 d’Ackermans & van Haaren SA (dont le siège social est établi à Begijnenvest 113, 2000 Anvers, Belgique). Ackermans & van Haaren a notifié qu'à la suite d'une acquisition d'actions supplémentaires le 28 octobre 2025, son nombre total de droits de vote dans Nextensa est passé à 80,31 % des droits de vote. Su...
OPENBAARMAKING VAN EEN TRANSPARANTIEKENNISGEVING - ACKERMANS & VAN HAAREN OPENBAARMAKING VAN EEN TRANSPARANTIEKENNISGEVING - ACKERMANS & VAN HAAREN Op grond van artikel 14 van de wet van 2 mei 2007, maakt Nextensa NV bekend dat het een transparantiekennisgeving heeft ontvangen gedateerd op 30 oktober 2025 van Ackermans & van Haaren NV (met zetel te Begijnenvest 113, 2000 Antwerpen, België). Ackermans & van Haaren heeft meegedeeld dat, ten gevolge van een verwerving van bijkomende aandelen, haar totaal aantal stemrechten in Nextensa op 28 oktober 2025 is toegenomen tot 80,31% van de stem...
Merus announced interim clinical data (29 July 2025 cutoff) from the ongoing phase 2 trial of petosemtamab (EGFR x LGR5 bispecific antibody) + standard of care FOLFOX/FOLFIRI (chemo) in 1L, 2L metastatic CRC (mCRC) and petosemtamab monotherapy in 3L+ mCRC. The results were presented at the AACR-NCI-EORTC, and confirm and build upon the responses reported from an initial dataset with a previous cut-off date (28 April 2025). We view the numbers as competitive vs. cetuximab (EGFR antibody) + FOLFOX...
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety – 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.